Latest Emerging Markets News

Vmoto Limited reported an 18% revenue decline to $46.8 million and a $9.9 million net loss in FY25, while accelerating its transformation into a full-stack electric mobility solutions provider with new global partnerships and product innovations.

Frontier Digital Ventures reported an 18% decline in statutory revenue to A$54.8 million for 2025, while operating EBITDA surged 205% to A$9.1 million, despite a net loss of A$18 million impacted by a significant goodwill impairment and a fraud incident in Colombia.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Kelsian Group Limited has reported a robust first half for FY26 with double-digit revenue growth and upgraded EBITDA guidance, alongside a strategic $161 million sale of its Tourism Portfolio.

XRF Scientific has reported a solid half-year performance, with revenue climbing 9.1% to $31.3 million and net profit after tax up 6%, driven by strong demand in mining and a standout Precious Metals division.

The a2 Milk Company has reported robust half-year results with strong revenue and earnings growth, driven by gains in infant formula and liquid milk segments, alongside a strategic supply chain transformation. The company has upgraded its full-year outlook and announced a substantial special dividend, signalling confidence in its growth trajectory.

Minbos Resources has appointed Rob Newbold as Acting CEO following the resignation of Lindsay Reed, while grappling with administrative and shareholder challenges delaying its key phosphate project in Angola.

GQG Partners delivered solid full-year 2025 results, with funds under management climbing 7.1% to US$163.9 billion and net income increasing 7.3% to US$463.3 million, despite net outflows. The firm maintained a strong dividend payout, reflecting confidence in its sustainable growth strategy.

GQG Partners reported a 7.1% increase in funds under management for 2025, driven by strong investment performance despite net outflows, while declaring a solid fourth-quarter dividend.

Cochlear Limited reported a modest 1% rise in HY26 sales revenue to $1.176 billion, but underlying net profit fell 9% amid slower-than-expected contract renewals for its new Nucleus Nexa implant system. The company anticipates a stronger second half and maintains full-year guidance at the lower end of its forecast.

Cochlear Limited reported a modest 1% rise in sales but a 9% fall in underlying net profit for the half year ended December 2025, as the rollout of its innovative Nucleus Nexa System faced longer-than-expected regulatory and contract hurdles. The company anticipates a robust second half driven by broader product availability and service growth.

Cochlear Limited posted a modest 1% increase in sales revenue for the half year ending December 2025, while underlying net profit fell 9%, impacted by cloud computing costs and a slower-than-expected Nexa System rollout. The company maintains its dividend and outlines cautious FY26 guidance.